Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Relmada Therapeutics (RLMD) Equity Ratio (2016 - 2026)

Relmada Therapeutics has reported Equity Ratio over the past 3 years, most recently at 3.12 for Q1 2014.

  • Quarterly Equity Ratio fell 1656.6% to 3.12 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was 3.12 through Feb 2014, down 1656.6% year-over-year, with the annual reading at 0.68 for FY2013, 210.3% down from the prior year.
  • Equity Ratio was 3.12 for Q1 2014 at Relmada Therapeutics, down from 2.28 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.62 in Q3 2012 and troughed at 4.5 in Q2 2013.
  • The 3-year median for Equity Ratio is 1.48 (2013), against an average of 1.69.
  • Year-over-year, Equity Ratio crashed 210.3% in 2013 and then plummeted 1656.6% in 2014.
  • A 3-year view of Equity Ratio shows it stood at 0.62 in 2012, then plummeted by 468.27% to 2.28 in 2013, then plummeted by 36.71% to 3.12 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Equity Ratio are 3.12 (Q1 2014), 2.28 (Q4 2013), and 0.68 (Q3 2013).